NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection
نویسندگان
چکیده
منابع مشابه
NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection
BACKGROUND Daclatasvir is an NS5A inhibitor approved for treatment of infection due to hepatitis C virus (HCV) genotypes (GTs) 1-4. To support daclatasvir use in HCV genotype 4 infection, we examined a diverse genotype 4-infected population for HCV genotype 4 subtype prevalence, NS5A polymorphisms at residues associated with daclatasvir resistance (positions 28, 30, 31, or 93), and their effect...
متن کاملheterogeneity and new epitopes of hepatitis c virus genotype 4
results the present work figured out that the heterogeneity of the quasispecies of our local strains 4a was high showing up 15% diversity. this study also showed four glycosylation sites that play an important role in the entry of the virus and protein folding. besides, different epitpoes were identified in different regions of the e1 and e2 domains; a finding which would help in determining th...
متن کاملComparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.
A comparison of the daclatasvir (DCV [BMS-790052]) resistance barrier on authentic or hybrid replicons containing NS5A from hepatitis C virus (HCV) genotypes 1 to 6 (GT-1 to -6) was completed using a replicon elimination assay. The data indicated that genotype 1b (GT-1b) has the highest relative resistance barrier and genotype 2a (GT-2a M31) has the lowest. The rank order of resistance barriers...
متن کاملHeterogeneity and New Epitopes of Hepatitis C Virus Genotype 4
BACKGROUND Hepatitis C virus (HCV) was found to have a major role in human liver disease by its ability to face the host-cell defenses and the immune system. Heterogeneity of HCV was the key for its adaptation to its host and represented a significant hurdle for the development of both effective vaccines as well as for novel therapeutic interventions. OBJECTIVES Due to the heterogeneity of HC...
متن کاملEfficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
BACKGROUND/AIMS The treatment strategy for hepatitis C virus (HCV) has been changing rapidly since the introduction of direct-acting antivirals such as daclatasvir (DCV) and asunaprevir (ASV). We evaluated the efficacy and safety of DCV and ASV for HCV in real-life practice. METHODS Patients were treated with 60 mg of DCV once daily plus 200 mg of ASV twice daily for 24 weeks, and followed fo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Infectious Diseases
سال: 2015
ISSN: 0022-1899,1537-6613
DOI: 10.1093/infdis/jiv379